Neumora Therapeutics (NMRA)

• Market cap: $331M
• 1 day: -5.53%
• 5 days: -5.53%
• 1 month: -81.14%
• 3 months: -87.91%
• 6 months: -82.77%
• Year to date: 4.06%
• 1 year: -85.54%
• 5 years: -87.38%
• 10 years: -87.38%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Employees: 109

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

55% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $9.43M

48% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 23

27% more capital invested

Capital invested by funds: $714M [Q2] → $906M (+$192M) [Q3]

11% more funds holding

Funds holding: 93 [Q2] → 103 (+10) [Q3]

2.66% less ownership

Funds ownership: 45.55% [Q2] → 42.89% (-2.66%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 241% upside
• Avg. target: $21 915% upside
• High target: $30 1,363% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

B of A Securities Geoff Meacham 41% 1-year accuracy 11 / 27 met price target	241% upside $7	Buy Maintained	6 Jan 2025
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target	1,363% upside $30	Buy Reiterated	3 Jan 2025
Needham Ami Fadia 41% 1-year accuracy 68 / 166 met price target	1,022% upside $23	Buy Reiterated	2 Jan 2025
RBC Capital Brian Abrahams 13% 1-year accuracy 10 / 79 met price target	1,315% upside $29	Outperform Reiterated	22 Nov 2024
JP Morgan Tessa Romero 24% 1-year accuracy 4 / 17 met price target	632% upside $15	Neutral Downgraded	5 Nov 2024